NCT01560416 2026-03-03
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
Clinical Trials
14 trialsNCT01602380 2026-02-27
FALCON
AstraZeneca
Phase 3 Completed
NCT05169567 2026-01-16
postMONARCH
Eli Lilly and Company
Phase 3 Active not recruiting
NCT04214288 2025-11-20
SERENA-2
AstraZeneca
Phase 2 Active not recruiting
NCT04975308 2025-07-11
EMBER-3
Eli Lilly and Company
Phase 3 Active not recruiting
NCT01441947 2025-05-25
Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT04738292 2024-05-03
Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)
University of Wisconsin, Madison
Phase 2 Terminated
NCT01953926 2024-03-12
SUMMIT
Puma Biotechnology, Inc.
Phase 2 Terminated
NCT02536742 2024-02-26
PYTHIA
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT04707196 2023-11-24
A Study of Abemaciclib in Indian Women With Advanced Breast Cancer
Eli Lilly and Company
Phase 4 Completed
NCT01610284 2020-08-25
BELLE-2
Novartis
Phase 3 Completed
NCT01633060 2019-01-30
BELLE-3
Novartis
Phase 3 Terminated
NCT00752986 2016-12-05
ZACFAST
Sanofi
Phase 2 Terminated
NCT00534417 2013-02-01
Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
Accelerated Community Oncology Research Network
Phase 2 Completed